Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on June 28, 2019. The filing addresses a regulatory notice regarding the company's listing status on the NASDAQ Capital Market following a one-for-twelve reverse stock split.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only quantitative metric disclosed is the number of publicly held shares, which stands at approximately 475,000 following the reverse stock split.
Material Changes
- Delisting Notice: The company received a notice from NASDAQ stating it no longer meets the minimum requirement of 500,000 publicly held shares under Listing Rule 5550(a)(4).
- Compliance Deadline: The company has until August 12, 2019, to submit a specific plan to regain compliance.
Outlook, Management Commentary, and Risks
Management expects to regain compliance with NASDAQ listing requirements upon the completion of two anticipated transactions expected to close in July 2019:
- An underwritten public offering of common stock pursuant to Registration Statement on Form S-1 (File No: 333-231508).
- The acquisition of Hesperix SA.
Upon closing these transactions, the company projects it will hold in excess of the 500,000 publicly held shares minimum.
Key Facts for Investor Verification
- Verify the closing status and timing of the underwritten public offering (Form S-1 File No: 333-231508).
- Confirm the closing of the acquisition of Hesperix SA.
- Monitor the company's submission of a compliance plan to NASDAQ by the August 12, 2019 deadline.
- Check subsequent filings to confirm the restoration of the minimum 500,000 publicly held shares.